Metastatic Ovarian Cancer Drug Market Report

Global and Region Metastatic Ovarian Cancer Drug Market Demand & Opportunity Outlook 2022-2028

  • POSTDATE：Aug 02, 2022
  • PAGES：213
  • REPORT CODE：GMM994051
  • REPORT SUMMARY
  • TABLE OF CONTENTS

  • The report details the trend, potential and market size of Metastatic Ovarian Cancer Drug market, and analyzes the current situation and prospects of the market from both qualitative and quantitative aspects, which can be roughly divided into three parts.

    The first part (Chapter1-7) mainly covers the qualitative analysis of Metastatic Ovarian Cancer Drugmarket, defines the market attractiveness level of Metastatic Ovarian Cancer Drug market through Porter's Five Forces Analysis, and summarizes the different factors in the overall environment through PEST analysis. Understand the distribution of industrial chain value in each link of industrial chain through the analysis of industrial chain structure. Thus estimate the market space of each link.

    The second part (Chapter8-12), based on the segmentation of Metastatic Ovarian Cancer Drug industry, describes the types of Metastatic Ovarian Cancer Drug market, the applications of major players and the market size, and deeply analyzes the current situation of the global Metastatic Ovarian Cancer Drug market and the development prospects and opportunities of Metastatic Ovarian Cancer Drug industry.

    The third part (Chapter14-15) includes the market positions of the major players and information on the market participants, which will help you gain a comprehensive understanding of the current competitive situation and potential growth opportunities in the market.

    As COVID-19 continues to impact the global economy in 2022, the report also considers the short - and long-term impacts of COVID-19 on the global Metastatic Ovarian Cancer Drug market in Chapter 13.

    By Player:

    • MolMed SpA

    • Millennium Pharmaceuticals Inc

    • Pfizer Inc

    • F Hoffmann-La Roche Ltd

    • Richter Gedeon Nyrt

    • Natco Pharma Limited

    • VG Life Sciences, Inc

    • Sumitomo Dainippon Pharma Co, Ltd

    • Cellceutix Corporation

    • Eisai Co, Ltd

    • Adgero Biopharmaceuticals Inc

    • Northwest Biotherapeutics, Inc

    • Immune Design Corp

    By Type:

    • E-7449

    • Crizotinib

    • CMB-305

    • G-305

    • LV-305

    • Others

    By End-User:

    • Clinic

    • Hospital

    • Others

    By Geography:

    • United States

    • Europe

    • China

    • Japan

    • India

    • South Korea

  • TABLE OF CONTENT

    1 Introduction

    • 1.1 Market Definition

    • 1.2 Market Segment Analysis

    • 1.3 Market Size 2022

    • 1.4 Metastatic Ovarian Cancer Drug Market Outlook: Forecast for 2022 - 2028

    • 1.5 Pricing Analysis

    2 Executive Summary

    3 Metastatic Ovarian Cancer Drug Market Lineage Outlook

    • 3.1 Parent Market Outlook

    • 3.2 Related/Ancillary Market Outlook

    • 3.3 Penetration & Growth Prospect Mapping, 2022

    4 Market Analysis Tools: Porter's Five Forces

    • 4.1 Supplier Power

    • 4.2 Buyer Power

    • 4.3 Substitution Threat

    • 4.4 Threat of New Entrants

    • 4.5 Competitive Rivalry

    5 Metastatic Ovarian Cancer Drug Industry Analysis - PEST (Political & Legal, Economic, Social, and Technological)

    • 5.1 Political/Legal Landscape

    • 5.2 Economic Landscape

    • 5.3 Social Landscape

    • 5.4 Technology Landscape

    6 Metastatic Ovarian Cancer Drug Market - Value Chain Analysis

    • 6.1 Industry's Value Chain Analysis

    • 6.2 Product Life Cycle

    • 6.3 User Perspective Analysis

    7 Region and Country-wise Metastatic Ovarian Cancer Drug Market Analysis and Outlook to 2022

    • 7.1 Global Metastatic Ovarian Cancer Drug Consumption (2017-2022)

    • 7.2 United States Metastatic Ovarian Cancer Drug Consumption (2017-2022)

    • 7.3 Europe Metastatic Ovarian Cancer Drug Consumption (2017-2022)

    • 7.4 China Metastatic Ovarian Cancer Drug Consumption (2017-2022)

    • 7.5 Japan Metastatic Ovarian Cancer Drug Consumption (2017-2022)

    • 7.6 India Metastatic Ovarian Cancer Drug Consumption (2017-2022)

    • 7.7 South Korea Metastatic Ovarian Cancer Drug Consumption (2017-2022)

    8 Region and Country-wise Metastatic Ovarian Cancer Drug Market Analysis and Outlook to 2028

    • 8.1 Global Metastatic Ovarian Cancer Drug Consumption Forecast (2022-2028)

    • 8.2 United States Metastatic Ovarian Cancer Drug Consumption Forecast (2022-2028)

    • 8.3 Europe Metastatic Ovarian Cancer Drug Consumption Forecast (2022-2028)

    • 8.4 China Metastatic Ovarian Cancer Drug Consumption Forecast (2022-2028)

    • 8.5 Japan Metastatic Ovarian Cancer Drug Consumption Forecast (2022-2028)

    • 8.6 India Metastatic Ovarian Cancer Drug Consumption Forecast (2022-2028)

    • 8.7 South Korea Metastatic Ovarian Cancer Drug Consumption Forecast (2022-2028)

    9 Global Metastatic Ovarian Cancer Drug Market Outlook by Types and Applications to 2022

    • 9.1 Global Metastatic Ovarian Cancer Drug Consumption and Growth Rate by Type (2017-2022)

      • 9.1.1 Global E-7449 Consumption and Growth Rate (2017-2022)

      • 9.1.2 Global Crizotinib Consumption and Growth Rate (2017-2022)

      • 9.1.3 Global CMB-305 Consumption and Growth Rate (2017-2022)

      • 9.1.4 Global G-305 Consumption and Growth Rate (2017-2022)

      • 9.1.5 Global LV-305 Consumption and Growth Rate (2017-2022)

      • 9.1.6 Global Others Consumption and Growth Rate (2017-2022)

    • 9.2 Global Metastatic Ovarian Cancer Drug Consumption and Growth Rate by Application (2017-2022)

      • 9.2.1 Global Clinic Consumption and Growth Rate (2017-2022)

      • 9.2.2 Global Hospital Consumption and Growth Rate (2017-2022)

      • 9.2.3 Global Others Consumption and Growth Rate (2017-2022)

    10 Global Metastatic Ovarian Cancer Drug Market Outlook by Types and Applications to 2028

    • 10.1 Global Metastatic Ovarian Cancer Drug Consumption Forecast and Growth Rate by Type (2022-2028)

      • 10.1.1 Global E-7449 Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.2 Global Crizotinib Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.3 Global CMB-305 Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.4 Global G-305 Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.5 Global LV-305 Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.6 Global Others Consumption Forecast and Growth Rate (2022-2028)

    • 10.2 Global Metastatic Ovarian Cancer Drug Consumption Forecast and Growth Rate by Application (2022-2028)

      • 10.2.1 Global Clinic Consumption Forecast and Growth Rate (2022-2028)

      • 10.2.2 Global Hospital Consumption Forecast and Growth Rate (2022-2028)

      • 10.2.3 Global Others Consumption Forecast and Growth Rate (2022-2028)

    11 Global Metastatic Ovarian Cancer Drug Import and Export Analysis (Top 5 Countries)

    • 11.1 Global Metastatic Ovarian Cancer Drug Import by Region (Top 5 Countries) (2017-2028)

    • 11.2 Global Metastatic Ovarian Cancer Drug Export by Region (Top 5 Countries) (2017-2028)

    12 Coronavirus Disease (COVID-19) Impact

    • 12.1 Industry Impact Analysis

    • 12.2 Metastatic Ovarian Cancer Drug Market Outlook to 2028 - COVID-19 Affected Forecasts

    13 Competition Matrix

    • 13.1 Target Markets

    • 13.2 Comprehensive Analysis of Products in Competitive Markets

    14 Global Metastatic Ovarian Cancer Drug Market Competitive Analysis

    • 14.1 MolMed SpA

      • 14.1.1 MolMed SpA Company Details

      • 14.1.2 MolMed SpA Metastatic Ovarian Cancer Drug Sales, Price, Value and Gross Profit (2017-2022)

      • 14.1.3 MolMed SpA Metastatic Ovarian Cancer Drug Product and Service

    • 14.2 Millennium Pharmaceuticals Inc

      • 14.2.1 Millennium Pharmaceuticals Inc Company Details

      • 14.2.2 Millennium Pharmaceuticals Inc Metastatic Ovarian Cancer Drug Sales, Price, Value and Gross Profit (2017-2022)

      • 14.2.3 Millennium Pharmaceuticals Inc Metastatic Ovarian Cancer Drug Product and Service

    • 14.3 Pfizer Inc

      • 14.3.1 Pfizer Inc Company Details

      • 14.3.2 Pfizer Inc Metastatic Ovarian Cancer Drug Sales, Price, Value and Gross Profit (2017-2022)

      • 14.3.3 Pfizer Inc Metastatic Ovarian Cancer Drug Product and Service

    • 14.4 F Hoffmann-La Roche Ltd

      • 14.4.1 F Hoffmann-La Roche Ltd Company Details

      • 14.4.2 F Hoffmann-La Roche Ltd Metastatic Ovarian Cancer Drug Sales, Price, Value and Gross Profit (2017-2022)

      • 14.4.3 F Hoffmann-La Roche Ltd Metastatic Ovarian Cancer Drug Product and Service

    • 14.5 Richter Gedeon Nyrt

      • 14.5.1 Richter Gedeon Nyrt Company Details

      • 14.5.2 Richter Gedeon Nyrt Metastatic Ovarian Cancer Drug Sales, Price, Value and Gross Profit (2017-2022)

      • 14.5.3 Richter Gedeon Nyrt Metastatic Ovarian Cancer Drug Product and Service

    • 14.6 Natco Pharma Limited

      • 14.6.1 Natco Pharma Limited Company Details

      • 14.6.2 Natco Pharma Limited Metastatic Ovarian Cancer Drug Sales, Price, Value and Gross Profit (2017-2022)

      • 14.6.3 Natco Pharma Limited Metastatic Ovarian Cancer Drug Product and Service

    • 14.7 VG Life Sciences, Inc

      • 14.7.1 VG Life Sciences, Inc Company Details

      • 14.7.2 VG Life Sciences, Inc Metastatic Ovarian Cancer Drug Sales, Price, Value and Gross Profit (2017-2022)

      • 14.7.3 VG Life Sciences, Inc Metastatic Ovarian Cancer Drug Product and Service

    • 14.8 Sumitomo Dainippon Pharma Co, Ltd

      • 14.8.1 Sumitomo Dainippon Pharma Co, Ltd Company Details

      • 14.8.2 Sumitomo Dainippon Pharma Co, Ltd Metastatic Ovarian Cancer Drug Sales, Price, Value and Gross Profit (2017-2022)

      • 14.8.3 Sumitomo Dainippon Pharma Co, Ltd Metastatic Ovarian Cancer Drug Product and Service

    • 14.9 Cellceutix Corporation

      • 14.9.1 Cellceutix Corporation Company Details

      • 14.9.2 Cellceutix Corporation Metastatic Ovarian Cancer Drug Sales, Price, Value and Gross Profit (2017-2022)

      • 14.9.3 Cellceutix Corporation Metastatic Ovarian Cancer Drug Product and Service

    • 14.10 Eisai Co, Ltd

      • 14.10.1 Eisai Co, Ltd Company Details

      • 14.10.2 Eisai Co, Ltd Metastatic Ovarian Cancer Drug Sales, Price, Value and Gross Profit (2017-2022)

      • 14.10.3 Eisai Co, Ltd Metastatic Ovarian Cancer Drug Product and Service

    • 14.11 Adgero Biopharmaceuticals Inc

      • 14.11.1 Adgero Biopharmaceuticals Inc Company Details

      • 14.11.2 Adgero Biopharmaceuticals Inc Metastatic Ovarian Cancer Drug Sales, Price, Value and Gross Profit (2017-2022)

      • 14.11.3 Adgero Biopharmaceuticals Inc Metastatic Ovarian Cancer Drug Product and Service

    • 14.12 Northwest Biotherapeutics, Inc

      • 14.12.1 Northwest Biotherapeutics, Inc Company Details

      • 14.12.2 Northwest Biotherapeutics, Inc Metastatic Ovarian Cancer Drug Sales, Price, Value and Gross Profit (2017-2022)

      • 14.12.3 Northwest Biotherapeutics, Inc Metastatic Ovarian Cancer Drug Product and Service

    • 14.13 Immune Design Corp

      • 14.13.1 Immune Design Corp Company Details

      • 14.13.2 Immune Design Corp Metastatic Ovarian Cancer Drug Sales, Price, Value and Gross Profit (2017-2022)

      • 14.13.3 Immune Design Corp Metastatic Ovarian Cancer Drug Product and Service

    15 Appendix


    TABLE OF CHARTS

    • Table Definition of Metastatic Ovarian Cancer Drug

    • Figure Metastatic Ovarian Cancer Drug Picture

    • Table Global Metastatic Ovarian Cancer Drug Market Size and Forecast 2022 - 2028 (USD million)

    • Figure Global Metastatic Ovarian Cancer Drug Market Size and Forecast 2022 - 2028 (USD million)

    • Figure Global Metastatic Ovarian Cancer Drug Market: Year-over-year Growth 2022 - 2028 (%)

    • Table Parent Market Analysis

    • Figure Parent Market Price

    • Table Related/Ancillary Market Outlook Analysis

    • Table Supplier Power Analysis

    • Table Buyer Power Analysis

    • Table Substitution Threat Analysis

    • Table Threat of New Entrants Analysis

    • Table Competitive Rivalry Analysis

    • Figure Global Metastatic Ovarian Cancer Drug Consumption by Country (2017-2022)

    • Figure United States Metastatic Ovarian Cancer Drug Consumption and Growth Rate (2017-2022)

    • Table Europe Metastatic Ovarian Cancer Drug Consumption and Growth Rate (2017-2022)

    • Figure China Metastatic Ovarian Cancer Drug Consumption and Growth Rate (2017-2022)

    • Figure Japan Metastatic Ovarian Cancer Drug Consumption and Growth Rate (2017-2022)

    • Figure India Metastatic Ovarian Cancer Drug Consumption and Growth Rate (2017-2022)

    • Figure South Korea Metastatic Ovarian Cancer Drug Consumption and Growth Rate (2017-2022)

    • Figure Global Metastatic Ovarian Cancer Drug Consumption Forecast by Country (2022-2028)

    • Figure United States Metastatic Ovarian Cancer Drug Consumption Forecast and Growth Rate (2022-2028)

    • Table Europe Metastatic Ovarian Cancer Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure China Metastatic Ovarian Cancer Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure Japan Metastatic Ovarian Cancer Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure India Metastatic Ovarian Cancer Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure South Korea Metastatic Ovarian Cancer Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global E-7449 Consumption and Growth Rate (2017-2022)

    • Figure Global Crizotinib Consumption and Growth Rate (2017-2022)

    • Figure Global CMB-305 Consumption and Growth Rate (2017-2022)

    • Figure Global G-305 Consumption and Growth Rate (2017-2022)

    • Figure Global LV-305 Consumption and Growth Rate (2017-2022)

    • Figure Global Others Consumption and Growth Rate (2017-2022)

    • Figure Global Clinic Consumption and Growth Rate (2017-2022)

    • Figure Global Hospital Consumption and Growth Rate (2017-2022)

    • Figure Global Others Consumption and Growth Rate (2017-2022)

    • Figure Global E-7449 Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Crizotinib Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global CMB-305 Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global G-305 Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global LV-305 Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Others Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Clinic Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Hospital Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Others Consumption Forecast and Growth Rate (2022-2028)

    • Table Global Metastatic Ovarian Cancer Drug Import by Region (Top 5 Countries) (2017-2028)

    • Table Global Metastatic Ovarian Cancer Drug Export by Region (Top 5 Countries) (2017-2028)

    • Table MolMed SpA (Foundation Year, Company Profile and etc.)

    • Table MolMed SpA Metastatic Ovarian Cancer Drug Sales, Price, Value and Gross Profit (2017-2022)

    • Table MolMed SpA Metastatic Ovarian Cancer Drug Product and Service

    • Table Millennium Pharmaceuticals Inc (Foundation Year, Company Profile and etc.)

    • Table Millennium Pharmaceuticals Inc Metastatic Ovarian Cancer Drug Sales, Price, Value and Gross Profit (2017-2022)

    • Table Millennium Pharmaceuticals Inc Metastatic Ovarian Cancer Drug Product and Service

    • Table Pfizer Inc (Foundation Year, Company Profile and etc.)

    • Table Pfizer Inc Metastatic Ovarian Cancer Drug Sales, Price, Value and Gross Profit (2017-2022)

    • Table Pfizer Inc Metastatic Ovarian Cancer Drug Product and Service

    • Table F Hoffmann-La Roche Ltd (Foundation Year, Company Profile and etc.)

    • Table F Hoffmann-La Roche Ltd Metastatic Ovarian Cancer Drug Sales, Price, Value and Gross Profit (2017-2022)

    • Table F Hoffmann-La Roche Ltd Metastatic Ovarian Cancer Drug Product and Service

    • Table Richter Gedeon Nyrt (Foundation Year, Company Profile and etc.)

    • Table Richter Gedeon Nyrt Metastatic Ovarian Cancer Drug Sales, Price, Value and Gross Profit (2017-2022)

    • Table Richter Gedeon Nyrt Metastatic Ovarian Cancer Drug Product and Service

    • Table Natco Pharma Limited (Foundation Year, Company Profile and etc.)

    • Table Natco Pharma Limited Metastatic Ovarian Cancer Drug Sales, Price, Value and Gross Profit (2017-2022)

    • Table Natco Pharma Limited Metastatic Ovarian Cancer Drug Product and Service

    • Table VG Life Sciences, Inc (Foundation Year, Company Profile and etc.)

    • Table VG Life Sciences, Inc Metastatic Ovarian Cancer Drug Sales, Price, Value and Gross Profit (2017-2022)

    • Table VG Life Sciences, Inc Metastatic Ovarian Cancer Drug Product and Service

    • Table Sumitomo Dainippon Pharma Co, Ltd (Foundation Year, Company Profile and etc.)

    • Table Sumitomo Dainippon Pharma Co, Ltd Metastatic Ovarian Cancer Drug Sales, Price, Value and Gross Profit (2017-2022)

    • Table Sumitomo Dainippon Pharma Co, Ltd Metastatic Ovarian Cancer Drug Product and Service

    • Table Cellceutix Corporation (Foundation Year, Company Profile and etc.)

    • Table Cellceutix Corporation Metastatic Ovarian Cancer Drug Sales, Price, Value and Gross Profit (2017-2022)

    • Table Cellceutix Corporation Metastatic Ovarian Cancer Drug Product and Service

    • Table Eisai Co, Ltd (Foundation Year, Company Profile and etc.)

    • Table Eisai Co, Ltd Metastatic Ovarian Cancer Drug Sales, Price, Value and Gross Profit (2017-2022)

    • Table Eisai Co, Ltd Metastatic Ovarian Cancer Drug Product and Service

    • Table Adgero Biopharmaceuticals Inc (Foundation Year, Company Profile and etc.)

    • Table Adgero Biopharmaceuticals Inc Metastatic Ovarian Cancer Drug Sales, Price, Value and Gross Profit (2017-2022)

    • Table Adgero Biopharmaceuticals Inc Metastatic Ovarian Cancer Drug Product and Service

    • Table Northwest Biotherapeutics, Inc (Foundation Year, Company Profile and etc.)

    • Table Northwest Biotherapeutics, Inc Metastatic Ovarian Cancer Drug Sales, Price, Value and Gross Profit (2017-2022)

    • Table Northwest Biotherapeutics, Inc Metastatic Ovarian Cancer Drug Product and Service

    • Table Immune Design Corp (Foundation Year, Company Profile and etc.)

    • Table Immune Design Corp Metastatic Ovarian Cancer Drug Sales, Price, Value and Gross Profit (2017-2022)

    • Table Immune Design Corp Metastatic Ovarian Cancer Drug Product and Service


Report Version Choose

Report

BUY NOW

Our Customers

Beyond grateful for the confidence and support from all partners and customers.A win-win situation is our ultimate pursuit.

Beyond Consulting, Future is Feasible

We provide more professional and intelligent market reports to complement your business decisions.

CONTACT US